Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival

被引:37
作者
Wimmer, K. [1 ,2 ]
Bolliger, M. [1 ,2 ]
Bago-Horvath, Z. [2 ,3 ]
Steger, G. [2 ,4 ]
Kauer-Dorner, D. [2 ,5 ]
Helfgott, R. [6 ]
Gruber, C. [7 ]
Moinfar, F. [7 ]
Mittlboeck, M. [8 ]
Fitzal, F. [1 ,2 ]
机构
[1] Med Univ Vienna, Dept Surg, Vienna, Austria
[2] Med Univ Vienna, Breast Hlth Ctr, Ctr Comprehens Canc, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Univ Vienna, Dept Med Oncol, Vienna, Austria
[5] Med Univ Vienna, Dept Radiooncol, Vienna, Austria
[6] Hosp Sisters Char, Ordensklinikum Linz, Dept Surg, Linz, Austria
[7] Hosp Sisters Char, Ordensklinikum Linz, Dept Pathol, Linz, Austria
[8] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
关键词
NEOADJUVANT CHEMOTHERAPY; CONSERVING THERAPY; SURGERY;
D O I
10.1245/s10434-019-08089-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background While "no tumour on ink" is an accepted margin width for R-0 resection in primary surgery, it's unclear if it's oncologically safe after neoadjuvant chemotherapy (NAC). Only limited data demonstrate that surgery within new margins in cases of a pathological complete response (pCR) is safe. We therefore investigated the influence of different margins and pCR on local recurrence and survival rates after NAC. Methods We retrospectively analysed data of 406 women with invasive breast cancer, treated with NAC and breast-conserving therapy between 1994 and 2014 in two certified Austrian breast health centres. We compared R <= 1 mm, R > 1 mm and RX (pCR) for local recurrence-free survival (LRFS), disease-free survival (DFS) and overall survival (OS). Results After a median follow-up of 84.3 months, the 5-year LRFS (R <= 1 mm: 94.2%, R > 1 mm: 90.6%, RX: 95.0%; p = 0.940), the 5-year DFS (R <= 1 mm: 71.9%, R > 1 mm: 74.1%, RX: 87.2%; p = 0.245) and the 5-year OS (R <= 1 mm: 85.1%, R > 1 mm: 88.0%, RX: 96.4%; p = 0.236) did not differ significantly between narrow, wide, nor RX resections. Regarding DFS and OS, a negative nodal status reduced the hazard ratio significantly. Conclusion There is no significant difference in LRFS, DFS and OS comparing close, wide or unknown margins after pCR. We suggest that resection in new margins after NAC is safe according to "no tumour on ink". Resection of the clipped area in cases of pCR is emphasized.
引用
收藏
页码:1700 / 1707
页数:8
相关论文
共 24 条
[1]   Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].
Alberro, J. A. ;
Ballester, B. ;
Deulofeu, P. ;
Fabregas, R. ;
Fraile, M. ;
Gubern, J. M. ;
Janer, J. ;
Moral, A. ;
de Pablo, J. L. ;
Penalva, G. ;
Puig, P. ;
Ramos, M. ;
Rojo, R. ;
Santesteban, P. ;
Serra, C. ;
Sola, M. ;
Solarnau, L. ;
Solsona, J. ;
Veloso, E. ;
Vidal, S. ;
Abe, O. ;
Abe, R. ;
Enomoto, K. ;
Kikuchi, K. ;
Koyama, H. ;
Masuda, H. ;
Nomura, Y. ;
Ohashi, Y. ;
Sakai, K. ;
Sugimachi, K. ;
Toi, M. ;
Tominaga, T. ;
Uchino, J. ;
Yoshida, M. ;
Coles, C. E. ;
Haybittle, J. L. ;
Moebus, V. ;
Leonard, C. F. ;
Calais, G. ;
Garaud, P. ;
Collett, V. ;
Davies, C. ;
Delmestri, A. ;
Sayer, J. ;
Harvey, V. J. ;
Holdaway, I. M. ;
Kay, R. G. ;
Mason, B. H. ;
Forbe, J. F. ;
Franci, P. A. .
LANCET ONCOLOGY, 2018, 19 (01) :27-39
[2]   Margins in Breast-Conserving Surgery After Neoadjuvant Therapy [J].
Choi, Jungeun ;
Laws, Alison ;
Hu, Jiani ;
Barry, William ;
Golshan, Mehra ;
King, Tari .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (12) :3541-3547
[3]  
Choi M, 2017, J PATHOL TRANSL MED, V51, P69, DOI 10.4132/jptm.2016.10.05
[4]   Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657 [J].
Esserman, Laura J. ;
Berry, Donald A. ;
DeMichele, Angela ;
Carey, Lisa ;
Davis, Sarah E. ;
Buxton, Meredith ;
Hudis, Cliff ;
Gray, Joe W. ;
Perou, Charles ;
Yau, Christina ;
Livasy, Chad ;
Krontiras, Helen ;
Montgomery, Leslie ;
Tripathy, Debasish ;
Lehman, Constance ;
Liu, Minetta C. ;
Olopade, Olufunmilayo I. ;
Rugo, Hope S. ;
Carpenter, John T. ;
Dressler, Lynn ;
Chhieng, David ;
Singh, Baljit ;
Mies, Carolyn ;
Rabban, Joseph ;
Chen, Yunn-Yi ;
Giri, Dilip ;
van 't Veer, Laura ;
Hylton, Nola .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3242-3249
[5]   Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study [J].
Fitzal, F. ;
Riedl, O. ;
Mittlboeck, M. ;
Dubsky, P. ;
Bartsch, R. ;
Steger, G. ;
Jakesz, R. ;
Gnant, M. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (01) :121-128
[6]   Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy [J].
Galvez, Marco ;
Castaneda, Carlos A. ;
Sanchez, Joselyn ;
Castillo, Miluska ;
Pamela Rebaza, Lia ;
Calderon, Gabriela ;
De La Cruz, Miguel ;
Manuel Cotrina, Jose ;
Abugattas, Julio ;
Dunstan, Jorge ;
Guerra, Henry ;
Mejia, Omar ;
Gomez, Henry L. .
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2018, 9 (02) :33-41
[7]   Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome [J].
Gentilini, Oreste ;
Intra, Mattia ;
Gandini, Sara ;
Peruzzotti, Giulia ;
Winnikow, Erik ;
Luini, Alberto ;
Veronesi, Paolo ;
Galimberti, Viviana ;
Goldhirsch, Aron ;
Veronesi, Umberto .
JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (05) :375-379
[8]   Breast Cancer Version 2.2015 [J].
Gradishar, William J. ;
Anderson, Benjamin O. ;
Balassanian, Ron ;
Blair, Sarah L. ;
Burstein, Harold J. ;
Cyr, Amy ;
Elias, Anthony D. ;
Farrar, William B. ;
Forero, Andres ;
Giordano, Sharon Hermes ;
Goetz, Matthew ;
Goldstein, Lori J. ;
Hudis, Clifford A. ;
Isakoff, Steven J. ;
Marcom, P. Kelly ;
Mayer, Ingrid A. ;
McCormick, Beryl ;
Moran, Meena ;
Patel, Sameer A. ;
Pierce, Lori J. ;
Reed, Elizabeth C. ;
Salerno, Kilian E. ;
Schwartzberg, Lee S. ;
Smith, Karen Lisa ;
Smith, Mary Lou ;
Soliman, Hatem ;
Somlo, George ;
Telli, Melinda ;
Ward, John H. ;
Shead, Dorothy A. ;
Kumar, Rashmi .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (04) :448-475
[9]   Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease [J].
Gralow, Julie R. ;
Burstein, Harold J. ;
Wood, William ;
Hortobagyi, Gabriel N. ;
Gianni, Luca ;
Von Minckwitz, Gunter ;
Buzdar, Aman U. ;
Smith, Ian E. ;
Symmans, William F. ;
Singh, Baljit ;
Winer, Eric P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :814-819
[10]   HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma [J].
Hou, Yanjun ;
Nitta, Hiroaki ;
Wei, Lai ;
Banks, Peter M. ;
Portier, Bryce ;
Parwani, Anil V. ;
Li, Zaibo .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) :447-457